<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259554</url>
  </required_header>
  <id_info>
    <org_study_id>19-1615-101</org_study_id>
    <nct_id>NCT04259554</nct_id>
  </id_info>
  <brief_title>OFC rTMS in Emotionally Unstable and Depressed Patients</brief_title>
  <acronym>ORIENT</acronym>
  <official_title>Orbitofrontal Cortex Transcranial Magnetic Stimulation in Patients With Emotionally Unstable Personality Disorder and Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of depression with conventional transcranial magnetic stimulation (rTMS) has shown
      high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation.
      Recently, it could be demonstrated that treatment of the right orbitofrontal cortex may be
      effective in patients who did not respond to conventional DLPFC rTMS. Orbitofrontal cortex
      (OFC) seem to be involved in the etiopathology of emotionally instable personality disorders.
      Thus, the present one-arm trial is a pilot study investigating if OFC rTMS is feasable,
      tolerable and effective.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton depression rating scale (HDRS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>measurment of depressivity: 21 items with a range 0-65 and higher values indicating higher scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory (MDI)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measurment of depressivity: 10 items with a range 0-50 and higher values indicating higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression (CGI)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measure of overall symptom severity and treatment response on a scale 1-7 with higher scores presenting more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression module of the Patient health questionnaire (PHQ-D)</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>measurment of depressivity: 9 items with a range 0-27 and higher values indicating higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barratt impulsiveness Scale (BIS)</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>measurment of impulsivity: 30 items with a range 0-120 and higher values indicating higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale of pain</measure>
    <time_frame>2 weeks, 4 weeks</time_frame>
    <description>Numeric rating scale of pain (the higher the score the higher the pain) with a range 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nicotine use</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>number of smoked cigarettes per day (the higher the value the higher the use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton depression rating scale (HDRS)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measurment of depressivity: 21 items with a range 0-65 and higher values indicating higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borderline Symptom List (BSL-23)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measurment of symptoms of borderline personality disorder: 23 items with a range 0-92 and higher values indicating higher scores</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Personality Disorder, Borderline</condition>
  <condition>Personality Disorder; Unstable</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>OFC rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OFC rTMS</intervention_name>
    <description>repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains รก 60 pulses with 30s intertrain-interval)</description>
    <arm_group_label>OFC rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICD-10: F60.30 or F60.31

          -  depressive symptoms and HAMD-21 score of at least 7

          -  sex: female and male

          -  residence in Germany and German speaking

          -  written informed consent

        Exclusion Criteria:

          -  meeting the contraindications for transcranial magnetic stimulation (electric devices
             or metal implants in the body, e.g. cardiac pace maker, insulin pump)

          -  neurological disorders (e.g. cerebrovascular events, neurodegenerative disorder,
             epilepsy, brain malformation, severe head trauma)

          -  participation in another study parallel to the Trial

          -  other mental or somatic illness which is not compatible with participation according
             to the principal investigator

          -  pregnancy or breastfeeding period

          -  psychiatric confinement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tobias Hebel, MD</last_name>
    <phone>+49-941-941-1250</phone>
    <email>tobias.hebel@medbo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schecklmann, PhD</last_name>
    <phone>+49-941-941-1250</phone>
    <email>martin.schecklmann@medbo.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Hebel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Schecklmann, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Berthold Langguth, MD, Ph.D.</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>rTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

